Targeting Therapeutics for the Middle and Inner Ear - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Targeting Therapeutics for the Middle and Inner Ear
A Conversation with Otonomy


Pharmaceutical Technology


PharmTech» Can other APIs be delivered this way?

»LeBel: Yes. The platform is very flexible and theoretically can be used for local delivery of small-molecule antibiotics to treat infections as well as small-molecule glutamate receptor antagonists to help treat certain kinds of hearing loss. In addition, we think it can be used to deliver larger molecule neurotrophic factors such as brain-derived neurotrophic factor or glial-cell line derived neurotrophic factor, which may alo be useful in treating hearing loss. We also imagine that we can combine the basic poloxamers with additional ingredients (e.g., permeabilizing agents, bulking agents, stabilizers, or solubilizers) as needed to optimize drug delivery.

PharmTech» Could this formulation be used to treat diseases in other organs?

»LeBel: Poloxamers are used in other pharmaceutical preparations to deliver drugs to the eye, gums, and abdomen. However, we're dedicated to treatments for inner- and middle-ear disorders at this time.

* http://Mayoclinic.com/ defines Meniere's disease as follows: Meniere's disease is a disorder of the inner ear that causes abnormal sensory perceptions, including a sensation of a spinning motion (vertigo), hearing loss usually in one ear, fullness or pressure in the same ear, and ringing in the same ear (tinnitus). People in their 40s and 50s are more likely than people in other age groups to develop Meniere's disease. Estimates of the number of people with Meniere's disease vary significantly, but according to the National Institute on Deafness and Other Communication Disorders, about 615,000 people in the United States have the disease.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here